MedTrace Logo

HYPAZ: Hypertension Induced by Pazopanib

NCT01392352 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-02-13

No results posted yet for this study

Summary

Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension). This side effect can make patients have to reduce or stop their cancer treatment, and can cause other health problems. The aim of this study is to find out exactly how the drug causes high blood pressure.

Conditions

Interventions

DRUG

Pazopanib

2 x 400mg pazopanib tablets taken once daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Duncan I Jodrell · University of Cambridge; honorary contract with Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2014-09-30
Completion
2015-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392352 on ClinicalTrials.gov